Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past week. The post StockWatch: Insilico Projects Profit,…
You may also like
SMC recommends VEOZA for moderate to severe menopausal...
SMC backs Columvi combination for second-line lymphoma...
Exonate appoints Olav Hellebø as CEO
New Lung Model Reveals RSV Immune Response, Points to...
Mung Bean Pan-Genome Study Maps Key Genes for Yield...
Immune Evasion Uncovered by Virome-Wide Ubiquitin...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.